Aktuellt
SENASTE
Yesterday Curasight presented some further information to the previously announced top line results of the ph2 trial in patients with primary gliomas presented on June 29. Patients with high uPAR uptake had significantly poorer prognosis than the low uptake group, more than a 10-fold difference in hazard ratio. The result confirms our expectations set by prior uPAR-targeting studies. Neutral.
LÄS MER
